Healthcare Sep 29, 2021 08:46 PM (GMT+8)
Yiouda health, September 29 - recently, together with researchers from five children's hospitals in the United States, the team of inmana scientists published a research report entitled "discovery of nicuseq random delay test" in JAMA Pediatrics, revealing that for critically ill newborns suspected of suffering from genetic diseases, clinical whole genome sequencing (cwgs) The application of is twice better than standard nursing in diagnosis effect and corresponding clinical management adjustment. This data provides a strong scientific basis for the wide use and implementation of clinical whole genome sequencing in critically ill newborns.
University of Nebraska Medical Center, Philadelphia children's Hospital (including the Monroe Mayer Institute), Omaha children's Hospital and medical center, orange children's Hospital, San Diego Ladi Institute of child genomics medicine, St. Louis Children's Hospital of the University of Washington, And le bonheur children's Hospital of the University of Tennessee Health Science Center in Memphis, Tennessee, participated in the study. The subjects included critically ill infants and young children from different ethnic groups and regions.
In this study, a population of 354 infants and young children were randomly assigned to receive clinical whole genome sequencing with a total observation period of 90 days within 15 days of admission (early group) or 60 days (delayed group). In the two research groups, the application of clinical whole genome sequencing doubled the proportion of patients who obtained accurate diagnosis and corresponding clinical management adjustment.
This text is a result of machine translation.